---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-207397"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:12:09.894395+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Inovio Q2 net loss $35.5M; stops VGX-3100 cervical program, cuts 30% staff

## Summary
- Net loss of $35.5M ($0.13 per share) on revenue of $226K; cash, equivalents & short-term investments $194.9M.
- Ceasing U.S. development of VGX-3100 for cervical HSIL after biomarker analysis; shifting focus to INO-3107 Phase 3 for RRP targeted for Q1 2024.
- Reducing workforce by 58 employees (30%) for ~$9.9M annual savings; cash runway extended into Q3 2025.
- R&D expenses fell to $23.7M from $56.5M; G&A dropped to $13.5M from $48.5M YoY, partly due to lower COVID-related costs and litigation settlement.
- ApolloBio continues VGX-3100 Phase 3 for cervical HSIL in China; INOVIO exploring anal HSIL and other pipeline candidates.

## SEC filing metadata
- accession: 0001193125-23-207397
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000119312523207397/0001193125-23-207397-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000119312523207397/d538749d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-207397
- JSON: https://secwatch.observer/filing/0001193125-23-207397.json
- Plain text: https://secwatch.observer/filing/0001193125-23-207397.txt

## Key facts
- Earnings Releases
  INOVIO PHARMACEUTICALS, INC. reported financial results for quarter and six months ended June 30, 2023.
  - Period: quarter and six months ended June 30, 2023
  - Result: reported results
  source text: On August 9, 2023, Inovio Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter and six months ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1055726/000119312523207397/0001193125-23-207397-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.